TY - JOUR
T1 - Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult
T2 - A Consensus Approach from the Trans-Atlantic RPS Working Group
AU - Trans-Atlantic RPS Working Group
AU - Ahlen, Jan
AU - Ahuja, Nita
AU - Antbacka, Robert
AU - Bagaria, Sanjay
AU - Blay, Jean Yves
AU - Bonvalot, Sylvie
AU - Callegaro, Dario
AU - Canter, Robert J.
AU - Cardona, Kenneth
AU - Casali, Paolo G.
AU - Colombo, Chiara
AU - Dei Tos, Angelo P.
AU - De Paoli, Antonino
AU - Desai, Anant
AU - Dickson, Brendan C.
AU - Eilber, Fritz C.
AU - Fiore, Marco
AU - Fletcher, Cristopher D.
AU - Ford, Samuel J.
AU - Gelderblom, Hans J.
AU - Gonzalez, Ricardo
AU - Grignani, Giovanni
AU - Grignol, Valerie
AU - Gronchi, Alessandro
AU - Haas, Rick L.
AU - Hayes, Andrew J.
AU - Hartmann, Wolfgang
AU - Henzler, Thomas
AU - Hohenberger, Peter
AU - Italiano, Antoine
AU - Jakob, Jens
AU - Jones, Robin L.
AU - Judson, Ian
AU - Kane, John M.
AU - Lahat, Guy
AU - MacNeill, Andrea J.
AU - Maestro, Roberta
AU - Messiou, Christina
AU - Meeus, Pierre
AU - Miceli, Rosalba
AU - Mullen, John T.
AU - Nessim, Carolyn
AU - Pennacchioli, Elisabetta
AU - Pillarisetty, Vinu G.
AU - Pollock, Raphael E.
AU - Quagliuolo, Vittorio
AU - Radaelli, Stefano
AU - Raut, Chandrajit P.
AU - Rutkowski, Piotr
AU - Wasif, Nabil
N1 - Publisher Copyright:
© 2016, Society of Surgical Oncology.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Introduction: Retroperitoneal soft tissue sarcomas (RPS) are rare tumors. Surgery is the mainstay of curative therapy, but local recurrence is common. No recommendations concerning the best management of recurring disease have been developed so far. Although every effort should be made to optimize the initial approach, recommendations to treat recurring RPS will be helpful to maximize disease control at recurrence. Methods: An RPS transatlantic working group was established in 2013. The goals of the group were to share institutional experiences, build large multi-institutional case series, and develop consensus documents on the approach to this difficult disease. The outcome of this document applies to recurrent RPS that is nonvisceral in origin. Included are sarcomas of major veins, undifferentiated pleomorphic sarcoma of psoas, ureteric leiomyosarcoma (LMS). Excluded are desmoids-type fibromatosis, angiomyolipoma, gastrointestinal stromal tumors, sarcomas arising from the gut or its mesentery, uterine LMS, prostatic sarcoma, paratesticular/spermatic cord sarcoma, Ewing sarcoma, alveolar/embryonal rhabdomyosarcoma, sarcoma arising from teratoma, carcinosarcoma, sarcomatoid carcinoma, clear cell sarcoma, radiation-induced sarcoma, paraganglioma, and malignant pheochromocytoma. Results: Recurrent RPS management was evaluated from diagnosis to follow-up. It is a rare and complex malignancy that is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, but some patients may experience prolonged disease control also at recurrence, when the approach is optimized and follows the recommendations contained herein. Conclusions: International collaboration is critical for adding to the present knowledge. A transatlantic prospective registry has been established.
AB - Introduction: Retroperitoneal soft tissue sarcomas (RPS) are rare tumors. Surgery is the mainstay of curative therapy, but local recurrence is common. No recommendations concerning the best management of recurring disease have been developed so far. Although every effort should be made to optimize the initial approach, recommendations to treat recurring RPS will be helpful to maximize disease control at recurrence. Methods: An RPS transatlantic working group was established in 2013. The goals of the group were to share institutional experiences, build large multi-institutional case series, and develop consensus documents on the approach to this difficult disease. The outcome of this document applies to recurrent RPS that is nonvisceral in origin. Included are sarcomas of major veins, undifferentiated pleomorphic sarcoma of psoas, ureteric leiomyosarcoma (LMS). Excluded are desmoids-type fibromatosis, angiomyolipoma, gastrointestinal stromal tumors, sarcomas arising from the gut or its mesentery, uterine LMS, prostatic sarcoma, paratesticular/spermatic cord sarcoma, Ewing sarcoma, alveolar/embryonal rhabdomyosarcoma, sarcoma arising from teratoma, carcinosarcoma, sarcomatoid carcinoma, clear cell sarcoma, radiation-induced sarcoma, paraganglioma, and malignant pheochromocytoma. Results: Recurrent RPS management was evaluated from diagnosis to follow-up. It is a rare and complex malignancy that is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, but some patients may experience prolonged disease control also at recurrence, when the approach is optimized and follows the recommendations contained herein. Conclusions: International collaboration is critical for adding to the present knowledge. A transatlantic prospective registry has been established.
UR - http://www.scopus.com/inward/record.url?scp=84982862155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982862155&partnerID=8YFLogxK
U2 - 10.1245/s10434-016-5336-7
DO - 10.1245/s10434-016-5336-7
M3 - Article
C2 - 27480354
AN - SCOPUS:84982862155
SN - 1068-9265
VL - 23
SP - 3531
EP - 3540
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 11
ER -